Back to mobile site

Merck (MRK) Immuno-Oncology Offering Lacks Combo; Goldman Maintains Neutral

June 3, 2013 3:34 PM EDT Send to a Friend
Goldman Sachs today maintained a Neutral rating on Merck (NYSE: MRK) and raised its price target to $50.00 (from $45.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login